BaEV lentiviral vectors – pushing the envelope of possibilities

Our baboon envelope pseudotyped (BaEV) lentiviral vector (LVV) platform offers a cutting-edge solution for transducing challenging cell types like NK cells, HSCs, and γδ T cells. Designed for efficiency and quality, this innovative approach improves transduction performance over traditional vectors (e.g., VSV-G), accelerating your journey to the clinic.
With our proven platform, you can expand your reach to new cell types with confidence.

Expertise you can trust

Transduction efficiency of 60–90% in NK and γδ T cells*

^{(in experiments run across 7 donors and multiple constructs)}

Proven performance in NK, HSCs, γδ T cells, and more to come!

BaEV LVV being evaluated in 7 research and preclinical programs

^{*Based on data collected through 2024. Miltenyi Biotec does not guarantee any specific results, or that batches will fully conform with any particular specifications. Individual success rate may vary based on factors such as client specifications.}

Leverage our BaEV LVV platform for your hard-to-transduce cells

New envelope, same proven manufacturing platform
Preclinical and GMP services fully developed and available
Exclusively at Miltenyi Bioindustry

Head-to-head comparison of BaEV LVV and VSV-G LVV in transducing NK cells

Transduction of NK cells with BaEV LVV expressing transgenes

Transduction of NK cells from 3 donors, comparing BaEV and VSV-G CAR expressing lentiviral vectors. BaEV LVV outperforms VSV-G LVV, and BaEV LVV expressing CAR is highly efficient at transducing NK cells.

Head-to-head comparison of BaEV LVV and VSV-G LVV in transducing γδ T cells

Transduction of γδ T cells with BaEV LVV expressing CAR

Transduction of γδ T cells from 4 donors, comparing BaEV and VSV-G CAR expressing lentiviral vectors. BaEV LVV outperforms VSV-G LVV, and BaEV LVV expressing CAR is highly efficient at transducing γδ T cells.

What you can expect:

A collaborative approach to evaluate if BaEV LVV is right for your program
Research-grade & preclinical vector for clinical trail enabling studies
From preclinical to GMP lentiviral vector in as little as 8.5 months*
Regulatory support through Regulatory Master File or Regulatory Support File

^{*Based on data collected through 2024. Miltenyi Biotec does not guarantee that any specific delivery date(s) will be met. Individual timelines may vary based on factors such as client’s stage of development and specifications.}